Fundraising FoxHalia Therapeutics
Lehi, US · Founded 2017 · Delaware corporation
Find your way into Halia Therapeutics
Each arrow is one introduction. Sign up to fill in the first one.
269 people can intro you to David
Ask Chris Yoo to introduce you to David Bearss
You →Chris · together at Systems Oncology →David
Sign up to find every way you can get introduced to Halia Therapeutics
- Your email: who you already know at Halia Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Halia Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Founders & leadership
Halia Therapeutics was founded in 2017 by David Bearss.
DB
David BearssCo-Founder, CEO and PresidentDavid Bearss has authored or co-authored over 80 scientific publications with more than 14,000 citations and is a named inventor on 80+ patent filings in oncology, inflammation, neurodegeneration, and precision medicine. He leads drug discovery and development at Halia Therapeutics and co-founded Biolexis Therapeutics, a platform combining computational chemistry and machine learning for cardiometabolic disease.
JB
Jeffrey BurtonExecutive
MM
Mike McCullarNamed on SEC filing
Board
TP
Todd PedersenBoard director
JS
Jim SavasBoard director
GB
Gary B. SabinBoard director
JB
Jared BearssBoard director
JS
John S.K. KauweBoard director
DC
David CheckettsBoard director
MB
Mary BeckerleBoard director
PC
Preston CampbellBoard director
Reported raises · per SEC filings
Form D private placements$27.4M disclosed across 5 rounds · 2020–2026
▶$3.5MraisedAug 2026 · 9 investors · BiotechnologyRule 506(b)
▶$3.5MraisedAug 2026 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey BurtonExecutive Officer
- David BearssDirector
- David CheckettsDirector
- John S.K. KauweDirector
- Gary B. SabinDirector
- Mary BeckerleDirector
- Preston CampbellDirector
- Offering amount
- $20M
- Amount sold
- $3.5M
- First sale
- Aug 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$336.8KraisedJul 2025 · 5 investors · BiotechnologyRule 506(b)
▶$336.8KraisedJul 2025 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jim SavasDirector
- David BearssExecutive Officer, Director
- Jeffrey BurtonExecutive Officer
- Gary B. SabinDirector
- Todd PedersenDirector
- Jared BearssDirector
- John S.K. KauweDirector
- Offering amount
- $20M
- Amount sold
- $336.8K
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$12.2MraisedDec 2022 · 24 investors · BiotechnologyRule 506(b)
▶$12.2MraisedDec 2022 · 24 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey BurtonExecutive Officer
- Jared BearssDirector
- David BearssExecutive Officer, Director
- John S.K. KauweDirector
- Jim SavasDirector
- Offering amount
- $50M
- Amount sold
- $12.2M
- First sale
- Dec 2022
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$5MraisedFeb 2021 · 5 investors · BiotechnologyRule 506(b)
▶$5MraisedFeb 2021 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- MIKE MCCULLARExecutive Officer, Director
- JIM SAVASDirector
- John S.K. KauweDirector, Promoter
- Jared BearssExecutive Officer, Director, Promoter
- David BearssExecutive Officer, Director, Promoter
- Offering amount
- $5M
- Amount sold
- $5M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$6.3MraisedOct 2020 · 9 investors · BiotechnologyRule 506(b)
▶$6.3MraisedOct 2020 · 9 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Mike McCullarExecutive Officer, Director
- Jim SavasDirector
- John S.K. KauweDirector, Promoter
- Jared BearssExecutive Officer, Director, Promoter
- David BearssExecutive Officer, Director, Promoter
- Offering amount
- $15M
- Amount sold
- $6.3M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who founded Halia Therapeutics?
- Halia Therapeutics was founded by David Bearss in 2017.
- How much funding has Halia Therapeutics raised?
- Halia Therapeutics has disclosed $27.4M raised across 5 rounds.
- Where is Halia Therapeutics headquartered?
- Halia Therapeutics is headquartered in Lehi, US.